The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | Moving towards a more dynamic strategy to determine eligibility for SCT in multiple myeloma
Gordon Cook, MB ChB, PhD, FRCP(Glas), FRCPath, Leeds Teaching Hospitals NHS Trust, Leeds, UK, comments on the limitations of current strategies used to define whether a patient with multiple myeloma is eligible to undergo stem cell transplantation (SCT) in the era of novel therapies. Whilst currently, this decision is made by a clinician using scoring systems, According to Prof. Cook, it is necessary to move towards a more dynamic approach, where a patient’s fitness is re-evaluated after trying to achieve disease control. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
